Core Viewpoint - A lawsuit has been filed against BioAge Labs, Inc. and its senior executives for potential violations of federal securities laws related to its initial public offering and subsequent trial discontinuation [1][2]. Group 1: Company Overview - BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, particularly obesity [3]. - The company's lead product candidate, azelaprag, is designed to enhance weight loss as an orally available small-molecule agonist of the apelin receptor [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 11 and 15 of the Securities Act of 1933, concerning investors who purchased stock during BioAge's IPO on September 26, 2024 [2]. - The case is currently pending in the U.S. District Court for the Northern District of California, titled Soto v. BioAge Labs, Inc., et al., No. 25-cv-196 [2]. Group 3: Clinical Trial and Safety Concerns - BioAge's IPO documents indicated ongoing STRIDES Phase 2 trial of azelaprag in combination with GLP-1R agonists, with expectations for topline results in Q3 2025 [4]. - The trial was discontinued due to safety concerns after subjects exhibited elevated liver enzyme levels, indicating potential organ damage [5]. - On December 6, 2024, BioAge announced the discontinuation of the STRIDES trial, leading to a significant stock price decline of over 76%, from 4.65 per share [6].
BIOA CLASS ACTION NOTICE: BioAge Labs Investors that Suffered Losses are Notified to Contact BFA Law before the March 10 Court Deadline (NASDAQ:BIOA)